Current/ Expected Orderbook/ Pending Orders?

Piramal Pharma's CDMO business shows a meaningfully better position in full-year revenue coverage from purchase orders (POs) and revenue booked compared to the same time last year. The company feels confident about its guidance based on the improved orderbook status. There is significant client interest, especially in complex areas like ADC (Antibody Drug Conjugates), with active customer engagement and potential projects underway, though long sales cycles exist. Increased activity includes inquiries, visits, audits, and RFPs linked to legislative changes impacting innovator customers, i

Any current/future new fundraising through debt or equity?

There is no mention of any current or immediate plans for new fundraising through debt or equity. The company has been focusing on reducing overall debt, with net debt-to-EBITDA ratio improving to 2.8x from 5x a year ago. Operating cash flows are expected to sufficiently support growth aspirations in CDMO, complex hospital generics, and consumer businesses. Investments and acquisitions so far have been funded through debt primarily aimed at growth-oriented projects. The management plans to balance internal accruals and investments based on emerging needs without indicating fresh fundraising. N

Any current/future capex/capital investment/strategic investment?

Piramal Pharma is making substantial progress on capex for Complex Hospital Generics (CHG), including adding new lines at Dahej and other plants, with expected benefits from FY '26 onwards. Investments continue in R&D and in-house product development to build a pipeline of limited competition, specialty products in CHG. Exploring new in-licensing deals to bring differentiated products to market and leverage distribution networks. Launched men's grooming brands on e-commerce with the potential to become Power Brands, with plans to expand offline once scaled. Overall, capital investments

Future growth expectations in sales/revenue/volumes?

The company registered a healthy revenue growth of 12% in Q1 FY'25. CDMO business delivered 18% year-on-year growth, expected to continue strong momentum. India Consumer Healthcare business exhibited steady double-digit growth with new product launches supporting growth. Complex Hospital Generics (CHG) plans to launch 5 approved products, with 17 more in the pipeline; specific approval timing is uncertain. Power Brands in Consumer Healthcare expected to grow faster than overall business, though no precise targets given. Expansion projects for sevoflurane capacity to come online in FY

Piramal PharmaQ1 FY25Pharmaceuticals & Biotechnology

Piramal Pharma Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹239.92Market Cap: ₹31.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company registered a healthy revenue growth of 12% in Q1 FY'25.
CDMO business delivered 18% year-on-year growth, expected to continue strong momentum.
India Consumer Healthcare business exhibited steady double-digit growth with new product launches supporting growth.
Complex Hospital Generics (CHG) plans to launch 5 approved products, with 17 more in the pipeline; specific approval timing is uncertain.
Power Brands in Consumer Healthcare expected to grow faster than overall business, though no precise targets given.
Expansion projects for sevoflurane capacity to come online in FY'26, aiming to capture growing demand.
Overall FY'25 guidance maintained: early teens year-on-year growth in revenue and absolute EBITDA with meaningful PAT increase.
Focus on cost optimization, better product mix, and increased process efficiencies aim to improve profitability alongside growth.

Margin guidance

Category 3

- Piramal Pharma aims for early teens year-on-year revenue growth in FY'25, supported by strong momentum in CDMO and India Consumer Healthcare businesses. - EBITDA for Q1 FY'25 grew 31% YoY with an 11% margin, supported by cost optimization and better product mix. - The company maintains its FY'25 guidance of early teens growth in revenue and absolute EBITDA with a meaningful PAT increase. - Management is focused on profitable growth, balancing advertising spends, especially towards Power Brands. - Operating margins are expected to improve progressively over time, but no specific near-term margin guidance provided. - The company believes in scaling its joint venture (AbbVie Therapeutics India Private Limited) and growing specialty products pipeline to boost future growth. - Debt reduction and sustainable capital management will support growth without impacting profitability. - Growth in Power Brands and new product launches are expected to drive Consumer Healthcare revenue growth. Overall, Piramal Pharma is confident about steady earnings growth while balancing margin improvement and sustainable expansion.

See what Piramal Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or immediate plans for new fundraising through debt or equity.
The company has been focusing on reducing overall debt, with net debt-to-EBITDA ratio improving to 2.8x from 5x a year ago.
Operating cash flows are expected to sufficiently support growth aspirations in CDMO, complex hospital generics, and consumer businesses.
Investments and acquisitions so far have been funded through debt primarily aimed at growth-oriented projects.
The management plans to balance internal accruals and investments based on emerging needs without indicating fresh fundraising.
No explicit guidance or statements about upcoming equity raise or additional debt issuance during the current year.

Order book

Yes

Piramal Pharma's CDMO business shows a meaningfully better position in full-year revenue coverage from purchase orders (POs) and revenue booked compared to the same time last year.
The company feels confident about its guidance based on the improved orderbook status.
There is significant client interest, especially in complex areas like ADC (Antibody Drug Conjugates), with active customer engagement and potential projects underway, though long sales cycles exist.
Increased activity includes inquiries, visits, audits, and RFPs linked to legislative changes impacting innovator customers, indicating growing demand.
However, many material order decisions are still pending as customers evaluate options.
Overall, order inflows remain steady and improved, supporting robust revenue growth and execution confidence.

See what Piramal Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

Piramal Pharma is making substantial progress on capex for Complex Hospital Generics (CHG), including adding new lines at Dahej and other plants, with expected benefits from FY '26 onwards.
Investments continue in R&D and in-house product development to build a pipeline of limited competition, specialty products in CHG.
Exploring new in-licensing deals to bring differentiated products to market and leverage distribution networks.
Launched men's grooming brands on e-commerce with the potential to become Power Brands, with plans to expand offline once scaled.
Overall, capital investments are focused on capacity expansion, new product development, and strengthening positions in key segments, with funding managed through internal accruals and reduced debt levels.

Track Piramal Pharma — get its next earnings analysis in your feed

How does Piramal Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisPiramal Pharma

Rev 3Mar 3

See where Piramal Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Piramal Pharma rank in Pharmaceuticals & Biotechnology?

Compare Piramal Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Piramal Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Piramal Pharma Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Piramal Pharma rank in Pharmaceuticals & Biotechnology?

Continue your research

What Piramal Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season